The type segment of the age-related macular degeneration market is bifurcated into dry AMD and wet AMD. Under this segment, the wet AMD category is expected to witness faster growth throughout the forecast period, owing to the soaring geriatric population and growing prevalence of wet AMD. According to the Bright Focus Foundation, nearly 10% of the total AMD cases are cases of wet AMD but are responsible for approximately 90% of legal blindness. As wet AMD is an advanced form of AMD, usage of drugs becomes extremely important in this stage.